Hydrodilatation Versus Arthroscopic Capsular Release for Frozen Shoulder

Sponsor
Royal Devon and Exeter NHS Foundation Trust (Other)
Overall Status
Completed
CT.gov ID
NCT03463538
Collaborator
(none)
50
1
2
48
1

Study Details

Study Description

Brief Summary

To compare the Oxford shoulder score at 6 months post intervention for primary frozen shoulder randomised to either an arthroscopic capsular release or hydro-dilatation

Condition or Disease Intervention/Treatment Phase
  • Procedure: arthroscopic capsular release
  • Procedure: Hydro-dilatation
N/A

Detailed Description

All potential participants for this study will be identified by an Orthopaedic Shoulder Consultant in the shoulder clinics run at the Royal Devon and Exeter NHS trust. The patients will be screened for eligibility by a research associate (SG). The eligibility criteria will be that the patient is medically fit for an operation, and has severe primary frozen shoulder in the acute painful stage, that is deemed suitable for intervention by the consultant surgeon. The patients will be informed verbally and in writing about the trial by the research associate and informed consent will be taken.

The participating patients will be randomised in a 1:1 allocation to arthroscopic capsular release (ACR) or hydrodilatation (HD). The randomisation will be administered by a central independent randomisation service, provided by a medical secretary using a computer generated randomisation sequence, who is completely independent of the trial.

All patients will be asked to fill out a number of questionnaires prior to surgery: the Oxford Shoulder Score (OSS) and the EQ-5D. The range of movement within the shoulder joint will be documented in a standard fashion.

Each patient will then undergo the assigned procedure according to the randomisation. The ACR would be performed by one of the Consultant Shoulder surgeons in their standard manner. The Hydro-dilatation would be performed by one of the Consultant Musculoskeletal radiologists in their standard manner. This would ensure that the options at each step of the operation or procedure, such as patient positioning, approach to the shoulder joint, and the closure of the wound etc are left entirely to the discretion of the Consultant performing the procedure. This will ensure that the results of the trial can be generalised to as wide a group of patients and surgeons as possible.

After the operation, patients will be reviewed using the range of movement, OSS, a patient satisfaction score and EQ-5D at 6 weeks, 3 months, and 6 months post-operatively. A record will be kept of any complications associated with the treatment. This data will be collected with by the research associate, who is independent of either intervention.

The main analysis will investigate differences in the primary outcome measure the OSS, between the two treatment groups (ACR and HD) on an intention-to-treat basis, at 6 months post-operation. Secondary outcome measures will be analysed in a similar manner. Statistical analysis will be undertaken by a statistician blinded to the interventions. Advice will be sought from an independent statistician provided by the trust to confirm the statistical methodology.

The economic evaluation will investigate the comparative cost-effectiveness of ACR versus HD. Health outcomes within 6 months follow-up will be assessed using the EuroQoL data collected within the trial, which will be valued using the standard UK TTO tariff to produce Quality-Adjusted Life-Year (QALY) estimates.

Study Design

Study Type:
Interventional
Actual Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
randomised control trial between interventionsrandomised control trial between interventions
Masking:
Single (Outcomes Assessor)
Masking Description:
independent clinical reviewer of patients ROM and collection of outcome scores
Primary Purpose:
Treatment
Official Title:
A Randomised Control Trial of Arthroscopic Capsular Release Versus Hydrodilatation for Primary Adhesive Capsulitis of the Shoulder
Actual Study Start Date :
Jun 1, 2013
Actual Primary Completion Date :
Dec 1, 2016
Actual Study Completion Date :
Jun 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Arthroscopic capsular release

Surgical release performed under general anesthetic

Procedure: arthroscopic capsular release
surgical release of shoulder joint capsule

Active Comparator: Hydro-dilatation

injection of water under local anesthetic in to shoulder joint

Procedure: Hydro-dilatation
dilatation of shoulder joint capsule using water pressure under local anesthetic

Outcome Measures

Primary Outcome Measures

  1. Oxford shoulder score [at 6months]

    Patient reported outcome with a maximum score of 48 and minimum of 0. 48 being the best outcome. Comprises 12 questions relating to pain and function specific to the shoulder

Secondary Outcome Measures

  1. Visual analogue score [at 6 months]

    pain score from 0 to 10 marked by patient on a continuous line. 0 being the worst score

  2. clinical assessment of range of movement (external rotation, internal rotation, forward flexion and abduction) [at 6 months]

    clinical assessment of range of movement using goniometer at the shoulder joint

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Medically fit for an operation; normal x-ray; Codmans criteria frozen shoulder
Exclusion Criteria:
  • Secondary causes of frozen shoulder; rotator cuff tears found at arthroscopy or hydro-dilatation; unable to adhere to trial protocol

Contacts and Locations

Locations

Site City State Country Postal Code
1 Royal Devon and Exeter hospital Exeter Devon United Kingdom

Sponsors and Collaborators

  • Royal Devon and Exeter NHS Foundation Trust

Investigators

  • Principal Investigator: chris smith, Royal Devon and Exeter

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Royal Devon and Exeter NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT03463538
Other Study ID Numbers:
  • 1312873
First Posted:
Mar 13, 2018
Last Update Posted:
Mar 14, 2018
Last Verified:
Mar 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 14, 2018